Curcumin resistance induced by hypoxia in HepG2 cells is mediated by multidrug-resistance-associated proteins

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5337-5342

  Sakulterdkiat, Titipatima ^a   Srisomsap, Chantragan ^c   Udomsangpetch, Rachanee ^a   Svasti, Jisnuson ^b,c   Lirdprapamongkol, Kriengsak ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Chulabhorn Research Institute ^*  (Thailand)

^c Krung Thep Maha Nakhon   (Thailand)

Author keywords

Curcumin; Doxorubicin; Drug resistance; Etoposide; Hepatocellular carcinoma; Hypoxia

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B2; ABC TRANSPORTER C1; ABC TRANSPORTER C2; ABC TRANSPORTER C3; BREAST CANCER RESISTANCE PROTEIN; CURCUMIN; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CURCUMIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84872532051     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Velingkar VS and Dandekar VD: Modulation of P-glycoprotein-mediated multidrug resistance (MDR) in cancer using chemosensitizers. Int J Pharma Sci Res 1: 104-111, 2010.
2. Hatcher H, Planalp R, Cho J, Torti F and Torti S: Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
3. López-Lázaro M: Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52: S103-S127, 2008.
4. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
5. Clinical Trials for Curcumin and Cancer. Clinical Trials Feeds; [last accessed February 11, 2012]; Available from: http://clinicaltrialsfeeds.org/ clinical-trials/results/term=curcumin+and+cancer?
6. Reuter S, Eifes S, Dicato M, Aggarwal BB and Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76: 1340-1351, 2008.
7. Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM and Oteiza PI: Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-κB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 123: 56-65, 2008.
8. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V and Aggarwal BB: Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis 28: 1765-1773, 2007.
9. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV and Limtrakul P-N: Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64: 573-582, 2002.
10. Tang X-Q, Bi H, Feng J-Q and Cao J-G: Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 26: 1009-1016, 2005.
11. Xiao H, Xiao Q, Zhang K, Zuo X and Shrestha U: Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol 89: 399-404, 2010.
12. Rak JW, Coomber B and Yu JL: Oncogenes and tumor suppressor genes in therapeutic resistance: The role of evolving interrelationships between cancer cells and host tissues. In: Cancer Drug Resistance. Teicher BA (ed.). New Jersey, Humana Press Inc., pp. 67-103, 2006.
13. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
14. Kuo MT: Redox regulation of multidrug resistance in cancer chemotherapy: Molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 11: 99-133, 2009.
15. Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
16. Ding Z, Yang L, Xie X, Xie F, Pan F, Li J, He J and Liang H: Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136: 1697-1707, 2010.
17. Milane L, Duan Z and Amiji M: Role of hypoxia and glycolysis in the development of multidrug resistance in human tumor cells and the establishment of an orthotopic multidrug-resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int 11: 3, 2011.
18. Liu L, Sun L, Zhang H, Li Z, Ning X, Shi Y, Guo C, Han S, Wu K and Fan D: Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance. Int J Cancer 124: 1707-1715, 2009.
19. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X and Yu J: Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemother Pharmacol 58: 776-784, 2006.
20. Lirdprapamongkol K, Mahidol C, Thongnest S, Prawat H, Ruchirawat S, Srisomsap C, Surarit R, Punyarit P and Svasti J: Anti-metastatic effects of aqueous extract of Helixanthera parasitica. J Ethnopharmacol 86: 253-256, 2003.
21. Kanintronkul Y, Worayuthakarn R, Thasana N, Winayanuwattikun P, Pattanapanyasat K, Surarit R, Ruchirawat S and Svasti J: Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones. Anticancer Res 31: 921-927, 2011.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
23. Chan LMS, Lowes S and Hirst BH: The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25-51, 2004.
24. Awasthi S, Pandya U, Singhal SS, Lin JT, Thiviyanathan V, Seifert Jr WE, Awasthi YC and Ansari GaS: Curcumin-glutathione interactions and the role of human glutathione S-transferase P1-1. Chem Biol Interact 128: 19-38, 2000.
25. Wortelboer HM, Usta M, Van Der Velde AE, Boersma MG, Spenkelink B, Van Zanden JJ, Rietjens IMCM, Van Bladeren PJ and Cnubben NHP: Interplay between MRP inhibition and metabolism of MRP inhibitors: The case of curcumin. Chem Res Toxicol 16: 1642-1651, 2003.
26. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK and Kim KW: Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15: 1557-1562, 2006.
27. Choi H, Chun Y-S, Kim S-W, Kim M-S and Park J-W: Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: A mechanism of tumor growth inhibition. Mol Pharmacol 70: 1664-1671, 2006.
28. Ströfer M, Jelkmann W and Depping R: Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells. Strahlenther Onkol 187: 393-400, 2011.
29. Bachmeier BE, Iancu CM, Killian PH, Kronski E, Mirisola V, Angelini G, Jochum M, Nerlich AG and Pfeffer U: Overexpression of the ATP binding cassette gene ABCA1 determines resistance to curcumin in M14 melanoma cells. Mol Cancer 8: 129, 2009.
30. Comerford KM, Wallace TJ, Karhausen JR, Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394, 2002.
31. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K and Fan D: Hypoxia-inducible factor-1α contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128, 2008.
32. Tada Y, Wada M, Migita T, Nagayama J, Hinoshita E, Mochida Y, Maehara Y, Tsuneyoshi M, Kuwano M and Naito S: Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 98: 630-635, 2002.
33. Zelcer N, Saeki T, Reid G, Beijnen JH and Borst P: Characterization of drug transport by the human multidrug-resistance protein 3 (ABCC3). J Biol Chem 276: 46400-46407, 2001.
34. Zhu H, Chen XP, Luo SF, Guan J, Zhang WG and Zhang BX: Involvement of hypoxia-inducible factor-1-α in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 24: 565-574, 2005.
35. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z and Brenner DE: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17: 1411-1417, 2008.
36. Lin JK and Lin-Shiau SY: Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc Repub China B 25: 59-66, 2001.